Health Care Policy Newsletter - June 2018

Foley’s Bipartisan Public Policy Team is pleased to share our “Public Policy Health Care Newsletter” in which we compile the latest health care policy news and legislation.

*Please note that we publish this newsletter only when Congress is in session.

Congress

Legislation and Committee Activity

House Passes First Package of Appropriations Bills – The House approved a package today – commonly called a “mini-bus” – of three fiscal year 2019 Appropriations bills, including Energy and Water, Military Construction and Veterans Affairs, and the Legislative Branch. Read More

Roll Call: Congress’ Focus on Opioids Misses Larger Crisis Congress faced a startling public health and political problem throughout 2016 as the number of people dying from opioid addiction climbed. The number of Americans succumbing to drug overdoses more than tripled between 1999 and 2015, affecting a whiter and more geographically diverse population than previous drug crises. Lawmakers ultimately approved some modest policies aimed at curbing prescription drug abuse and provided $1 billion to support state efforts. Read More

Politico: Bill Cassidy Doesn’t Want to be ‘Don Quixote’ on ACA Repeal – Sen. Bill Cassidy (R-LA), co-author of a high-profile Obamacare repeal bill, isn’t so sure Congress should take another crack at undoing the law this year. However, he said lawmakers should move on legislation to make health care more affordable. Read More Read More

Hearing on Lowering Costs and Expanding Access to Health care through Consumer – Directed Health Plans On Wednesday, the House Ways and Means Committee held a hearing on lowering costs and expanding access to health care through consumer-directed health plans. Read More Read More

Walden and Burgess on 2018 Medicare Trustees Report Energy and Commerce Committee Chairman Greg Walden (R-OR) and Health Subcommittee Chairman Michael C. Burgess, M.D. (R-TX) issued the following statement after the release of the 2018 Medicare Trustees Report. Read More Read More

Bipartisan E&C, Senate HELP Leaders Press HHS for Answers on Health Care Cybersecurity Efforts – On Tuesday, bipartisan and bicameral health care leaders sent a letter to HHS raising concerns about the department’s implementation of a portion of the Cybersecurity Information Sharing Act (CISA) of 2015. The leaders requested information regarding the “Cyber Threat Preparedness Report” (CTPR), as well as other important status updates. Read More

HHS Secretary Azar Testifies Before Education and Workforce Committee On Wednesday, the Committee on Education and the Workforce, chaired by Rep. Virginia Foxx (R-NC), held an oversight hearing with Department of Health and Human Services (HHS) Secretary Alex Azar to review the Department’s policies and priorities. Read More

Alexander, Bennet Introduce “PREEMIE” Bill to Give Infants Hope for Healthier Lives On Thursday, Sens. Lamar Alexander (R-TN) and Michael Bennet (D-CO) introduced the PREEMIE Act (S. 3029) to revise and extend the Prematurity Research Expansion and Education for Mothers who deliver Infants Early Act. Reps. Anna Eshoo (D-CA) and Leonard Lance (R-NJ) are expected to introduce companion legislation in the House of Representatives. Read More

Politico: McConnell Cancels Most of August Recess Sen. Majority Leader Mitch McConnell (R-KY) is canceling all but a week of the Senate’s traditional August recess, hoping to keep vulnerable Democrats off the campaign trail and confirm as many of President Donald Trump’s judicial and executive branch nominees as possible. Read More

Administration

Statement from the Press Secretary Regarding the Youth Opioid Prevention Ad Campaign Today, the Administration unveiled the first set of public awareness ads to combat the opioid crisis. The first set of ads is focused on preventing young adults, ages 18-24, from misusing or abusing opioids. Read More

Chairman Pai Proposes Funding Increase for Rural Health Care Program – Federal Communications Commission Chairman Ajit Pai announced that he has circulated a draft order to his colleagues that would take immediate action to significantly increase funding for the Universal Service Fund’s Rural

Health Care Program. Read More

HHS

Politico: Trump Seeks to Reorganize the Federal Government – The Trump administration is preparing to release a sweeping plan for reorganizing the federal government that includes a major consolidation of welfare programs — and a renaming of the Health and Human Services Department. Read More

Readout of HHS Secretary Azar’s Roundtable with Medical Device Leaders On Thursday, HHS Secretary Alex Azar held a roundtable discussion with leaders from medical device companies and the industry group AdvaMed. The gathering was part of ongoing efforts at HHS to explore ways to break down barriers to innovation as part of the Trump Administration’s work to improve health care in the United States. Read More

Health Care Informatics: The Push Towards Value – Based Care is Forcing the HIT Vendor Market Forward The health care policy and payment landscape is rapidly evolving, with the move to value-based care models a driving force behind current health care reform efforts. Case in point: in a recent speech at the World Health Care Congress, Health and Human Services (HHS) Secretary Alex Azar laid out his agency’s overall policy strategy and cited accelerating the value-based transformation of the Health care system as a top priority. Read More

NIH releases strategic plan for data science Storing, managing, standardizing and publishing the vast amounts of data produced by biomedical research is a critical mission for the National Institutes of Health. In support of this effort, NIH today released its first Strategic Plan for Data Science that provides a roadmap for modernizing the NIH-funded biomedical data science ecosystem. Read More

CMS

The Hill: Watchdog Report Finds surge in Medicare Drug Spending – Medicare spending on prescription drugs has surged in recent years, despite a drop in the number of prescriptions, according to a new report. The report from the Department of Health and Human Services (HHS) inspector general finds that Medicare Part D spending for brand-name drugs rose by 62 percent from 2011 to 2015, from $49 billion to $80 billion. Read More

Medicare Funds Drying Up Faster Than Estimated – The Medicare trust fund will be insolvent by 2026, three years earlier than estimates released by the Trump administration last year. That’s partly due to the Tax Cuts and Jobs Act which called for eliminating the individual mandate, according to the 2018 Medicare Trustee Report released Tuesday. Read More

Fierce Health Care: CMS Unveils Medicaid/CHIP ‘Scorecard’ Data – The Trump administration released the inaugural Medicaid and CHIP “scorecard” on June 4, which is intended to reveal how states are performing under the programs. Read More

Modern Health Care: White House Officials Call for ACO Rule Changes – Accountable Care Organizations are failing to meet their promise to save Medicare money, and regulations governing the model need to change, according to senior White House official. Read More

GAO Report: Medicare Needs Better Information to Reduce the Risk of Harm to Beneficiaries – In late May, GAO released a report of Medicare’s efforts to reduce inappropriate opioid prescribing. We suggested ways to help Medicare collect information on doctor investigations and at-risk beneficiaries that could help it determine whether its efforts are working. Read More

GAO Report: CMS Should Take Steps to Mitigate Program Risks in Managed Care – On Wednesday, CMS released a report on Steps to Mitigate Program Risks in Managed Care. Read More

FDA

FDA Takes Action Against 53 Websites Marketing Unapproved Opioids as Part of a Comprehensive Effort to Target Illegal Online Sales – The U.S. Food and Drug Administration announced that it has warned nine online networks, operating a total of 53 websites, that they must stop illegally marketing potentially dangerous, unapproved and misbranded versions of opioid medications, including tramadol and oxycodone. Read More

FDA Approves First Biosimilar to Neulasta to Help Reduce the Risk of Infection During Cancer Treatment – On Monday, the FDA approved Fulphila as the first biosimilar to Neulasta to decrease the chance of infection as suggested by febrile neutropenia (fever, often with other signs of infection, associated with an abnormally low number of infection-fighting white blood cells), in patients with non-myeloid (non-bone marrow) cancer who are receiving myelosuppressive chemotherapy that has a clinically significant incidence of febrile neutropenia. Read More

Veterans Affairs

USA Today: Trump Signs VA Law to Provide Veterans More Private Health Care Choices – President Trump signed legislation Wednesday paving the way for a major overhaul of the Department of Veterans Affairs and expanded access for veterans to VA-funded care in the private sector. Read More

States

Gov. Northam Signs Virginia Budget, Medicaid Expansion Bill – Governor Ralph Northam signed two bills Thursday that will fund the Commonwealth of Virginia’s government for the rest of Fiscal Year 2018 and all of Fiscal Years 2019 and 2020. Read More

ABC News: Medicaid Work Requirement Bill Sent to Michigan Governor – The Republican-led Michigan Legislature on Thursday gave final approval to a bill requiring able-bodied adults in the state’s Medicaid expansion program to meet work or job-related requirements, sending it to Gov. Rick Snyder for his expected signature. Read More

Washington Post: Trump Administration Won’t Defend ACA in Case Brought by GOP States – The Trump administration said Thursday night that it will not defend the Affordable Care Act against the latest legal challenge to its constitutionality — a dramatic break from the executive branch’s tradition of arguing to uphold existing statutes and a land mine for health insurance changes the ACA brought about. Read More

Primaries

California – Sen. Dianne Feinstein (D-CA) and Lt. Gov Gavin Newsom won early victories. Feinstein will face Democratic State Senator Kevin De Leon and Newsom will face Republican John Cox.

Montana – State auditor and insurance commissioner Matt Rosendale will take on Senator Jon Tester (D-MT) in November.

New Mexico – Rep. Michelle Lujan Grisham (D-MN) clinched the Democratic nomination for governor.

Iowa – Democrat Pete D’Alessandro will face Rep. David Young (R-IA) in the Iowa 3rd district.

Vox: 5 Winners and 2 Losers From the First Set of this Week’s Primary Elections – June 5 was the biggest primary day of the year — but it may take some time before all the election results are clear. Read More

On June 12, Maine, Nevada, North Dakota, South Carolina and Virginia will head to the polls.

Foley Health Care Law Today

Our attorneys at Foley pride themselves on having a first-hand understanding of health care’s business and legal challenges. Health Care Law Today is your go-to resource for information and perspectives on the latest news and developments in Health care law and how it relates to and impacts the industry and those with related business interests. For some of the blog’s top stories see below:

The VA Mission Act of 2018 and Potential Opportunities for Providers – After a concerted effort, the bipartisan bill to reform the way care is delivered to Veterans has been signed into law. While there are a number of significant reforms, perhaps none are so critical as those related to the ability of Covered Veterans to receive their care outside of the current VA system. Read More

Orthopedics: The New Darling of Private Equity – The past decade has seen a tremendous amount of private equity investment in physician practice recapitalizations, primarily in hospital-based practices such as anesthesiology and radiology as well as “retail medicine practices” like dermatology and ophthalmology/optometry, to name a few. Read More

Looking Ahead

The House and Senate are Both in Session Next Week.

Majority Leader Kevin McCarthy (R-CA) announced in an end-of-week leadership colloquy that the House will vote on several opioid measures next week. The House will consider H.R. 2851 that would establish a new category of synthetic opioids and other drugs under the Controlled Substances Act; H.R. 5735 that would set aside low-income housing vouchers to help people recovering from addiction; and H.R. 5788 that would close loopholes in international shipping to stop the flow of synthetic opioids. First votes are Tuesday at 6:30pm; last votes are no later than 3:00pm.

On Monday, the House Rules Committee will begin setting debate parameters for a synthetic analogue control measure – Stop the Importation and Trafficking of Synthetic Analogues Act of 2017 (H.R. 2851). Read More

On Tuesday, the Senate Judiciary Committee will hold a markup on the combined opioid response package – the Preventing Drug Diversion Act of 2018 (S. 2837). Read More

On Tuesday, the Senate HELP Committee will hold a hearing on Trump’s drug pricing plan. HHS Secretary Alex Azar will testify. Read More

On Tuesday, the Senate Finance Committee will hold a markup on the Helping to End Addiction and Lessen (HEAL) Substance Use Disorders Act of 2018, which seeks to improve Medicare, Medicaid and human services programs’ response to the opioid crisis. Read More

On Wednesday, the House Veteran Affairs Committee will hold a hearing on six Health care measures and two draft bills. Read More

On June 19, the Senate HELP Committee will hold a hearing on the Effective Administration of the 340B Drug Pricing Program. Read More

DISCLAIMER: Because of the generality of this update, the information provided herein may not be applicable in all situations and should not be acted upon without specific legal advice based on particular situations.

© Foley & Lardner LLP | Attorney Advertising

Written by:

Foley & Lardner LLP
Contact
more
less

Foley & Lardner LLP on:

Readers' Choice 2017
Reporters on Deadline

"My best business intelligence, in one easy email…"

Your first step to building a free, personalized, morning email brief covering pertinent authors and topics on JD Supra:
*By using the service, you signify your acceptance of JD Supra's Privacy Policy.
Custom Email Digest
- hide

JD Supra Privacy Policy

Updated: May 25, 2018:

JD Supra is a legal publishing service that connects experts and their content with broader audiences of professionals, journalists and associations.

This Privacy Policy describes how JD Supra, LLC ("JD Supra" or "we," "us," or "our") collects, uses and shares personal data collected from visitors to our website (located at www.jdsupra.com) (our "Website") who view only publicly-available content as well as subscribers to our services (such as our email digests or author tools)(our "Services"). By using our Website and registering for one of our Services, you are agreeing to the terms of this Privacy Policy.

Please note that if you subscribe to one of our Services, you can make choices about how we collect, use and share your information through our Privacy Center under the "My Account" dashboard (available if you are logged into your JD Supra account).

Collection of Information

Registration Information. When you register with JD Supra for our Website and Services, either as an author or as a subscriber, you will be asked to provide identifying information to create your JD Supra account ("Registration Data"), such as your:

  • Email
  • First Name
  • Last Name
  • Company Name
  • Company Industry
  • Title
  • Country

Other Information: We also collect other information you may voluntarily provide. This may include content you provide for publication. We may also receive your communications with others through our Website and Services (such as contacting an author through our Website) or communications directly with us (such as through email, feedback or other forms or social media). If you are a subscribed user, we will also collect your user preferences, such as the types of articles you would like to read.

Information from third parties (such as, from your employer or LinkedIn): We may also receive information about you from third party sources. For example, your employer may provide your information to us, such as in connection with an article submitted by your employer for publication. If you choose to use LinkedIn to subscribe to our Website and Services, we also collect information related to your LinkedIn account and profile.

Your interactions with our Website and Services: As is true of most websites, we gather certain information automatically. This information includes IP addresses, browser type, Internet service provider (ISP), referring/exit pages, operating system, date/time stamp and clickstream data. We use this information to analyze trends, to administer the Website and our Services, to improve the content and performance of our Website and Services, and to track users' movements around the site. We may also link this automatically-collected data to personal information, for example, to inform authors about who has read their articles. Some of this data is collected through information sent by your web browser. We also use cookies and other tracking technologies to collect this information. To learn more about cookies and other tracking technologies that JD Supra may use on our Website and Services please see our "Cookies Guide" page.

How do we use this information?

We use the information and data we collect principally in order to provide our Website and Services. More specifically, we may use your personal information to:

  • Operate our Website and Services and publish content;
  • Distribute content to you in accordance with your preferences as well as to provide other notifications to you (for example, updates about our policies and terms);
  • Measure readership and usage of the Website and Services;
  • Communicate with you regarding your questions and requests;
  • Authenticate users and to provide for the safety and security of our Website and Services;
  • Conduct research and similar activities to improve our Website and Services; and
  • Comply with our legal and regulatory responsibilities and to enforce our rights.

How is your information shared?

  • Content and other public information (such as an author profile) is shared on our Website and Services, including via email digests and social media feeds, and is accessible to the general public.
  • If you choose to use our Website and Services to communicate directly with a company or individual, such communication may be shared accordingly.
  • Readership information is provided to publishing law firms and authors of content to give them insight into their readership and to help them to improve their content.
  • Our Website may offer you the opportunity to share information through our Website, such as through Facebook's "Like" or Twitter's "Tweet" button. We offer this functionality to help generate interest in our Website and content and to permit you to recommend content to your contacts. You should be aware that sharing through such functionality may result in information being collected by the applicable social media network and possibly being made publicly available (for example, through a search engine). Any such information collection would be subject to such third party social media network's privacy policy.
  • Your information may also be shared to parties who support our business, such as professional advisors as well as web-hosting providers, analytics providers and other information technology providers.
  • Any court, governmental authority, law enforcement agency or other third party where we believe disclosure is necessary to comply with a legal or regulatory obligation, or otherwise to protect our rights, the rights of any third party or individuals' personal safety, or to detect, prevent, or otherwise address fraud, security or safety issues.
  • To our affiliated entities and in connection with the sale, assignment or other transfer of our company or our business.

How We Protect Your Information

JD Supra takes reasonable and appropriate precautions to insure that user information is protected from loss, misuse and unauthorized access, disclosure, alteration and destruction. We restrict access to user information to those individuals who reasonably need access to perform their job functions, such as our third party email service, customer service personnel and technical staff. You should keep in mind that no Internet transmission is ever 100% secure or error-free. Where you use log-in credentials (usernames, passwords) on our Website, please remember that it is your responsibility to safeguard them. If you believe that your log-in credentials have been compromised, please contact us at privacy@jdsupra.com.

Children's Information

Our Website and Services are not directed at children under the age of 16 and we do not knowingly collect personal information from children under the age of 16 through our Website and/or Services. If you have reason to believe that a child under the age of 16 has provided personal information to us, please contact us, and we will endeavor to delete that information from our databases.

Links to Other Websites

Our Website and Services may contain links to other websites. The operators of such other websites may collect information about you, including through cookies or other technologies. If you are using our Website or Services and click a link to another site, you will leave our Website and this Policy will not apply to your use of and activity on those other sites. We encourage you to read the legal notices posted on those sites, including their privacy policies. We are not responsible for the data collection and use practices of such other sites. This Policy applies solely to the information collected in connection with your use of our Website and Services and does not apply to any practices conducted offline or in connection with any other websites.

Information for EU and Swiss Residents

JD Supra's principal place of business is in the United States. By subscribing to our website, you expressly consent to your information being processed in the United States.

  • Our Legal Basis for Processing: Generally, we rely on our legitimate interests in order to process your personal information. For example, we rely on this legal ground if we use your personal information to manage your Registration Data and administer our relationship with you; to deliver our Website and Services; understand and improve our Website and Services; report reader analytics to our authors; to personalize your experience on our Website and Services; and where necessary to protect or defend our or another's rights or property, or to detect, prevent, or otherwise address fraud, security, safety or privacy issues. Please see Article 6(1)(f) of the E.U. General Data Protection Regulation ("GDPR") In addition, there may be other situations where other grounds for processing may exist, such as where processing is a result of legal requirements (GDPR Article 6(1)(c)) or for reasons of public interest (GDPR Article 6(1)(e)). Please see the "Your Rights" section of this Privacy Policy immediately below for more information about how you may request that we limit or refrain from processing your personal information.
  • Your Rights
    • Right of Access/Portability: You can ask to review details about the information we hold about you and how that information has been used and disclosed. Note that we may request to verify your identification before fulfilling your request. You can also request that your personal information is provided to you in a commonly used electronic format so that you can share it with other organizations.
    • Right to Correct Information: You may ask that we make corrections to any information we hold, if you believe such correction to be necessary.
    • Right to Restrict Our Processing or Erasure of Information: You also have the right in certain circumstances to ask us to restrict processing of your personal information or to erase your personal information. Where you have consented to our use of your personal information, you can withdraw your consent at any time.

You can make a request to exercise any of these rights by emailing us at privacy@jdsupra.com or by writing to us at:

Privacy Officer
JD Supra, LLC
10 Liberty Ship Way, Suite 300
Sausalito, California 94965

You can also manage your profile and subscriptions through our Privacy Center under the "My Account" dashboard.

We will make all practical efforts to respect your wishes. There may be times, however, where we are not able to fulfill your request, for example, if applicable law prohibits our compliance. Please note that JD Supra does not use "automatic decision making" or "profiling" as those terms are defined in the GDPR.

  • Timeframe for retaining your personal information: We will retain your personal information in a form that identifies you only for as long as it serves the purpose(s) for which it was initially collected as stated in this Privacy Policy, or subsequently authorized. We may continue processing your personal information for longer periods, but only for the time and to the extent such processing reasonably serves the purposes of archiving in the public interest, journalism, literature and art, scientific or historical research and statistical analysis, and subject to the protection of this Privacy Policy. For example, if you are an author, your personal information may continue to be published in connection with your article indefinitely. When we have no ongoing legitimate business need to process your personal information, we will either delete or anonymize it, or, if this is not possible (for example, because your personal information has been stored in backup archives), then we will securely store your personal information and isolate it from any further processing until deletion is possible.
  • Onward Transfer to Third Parties: As noted in the "How We Share Your Data" Section above, JD Supra may share your information with third parties. When JD Supra discloses your personal information to third parties, we have ensured that such third parties have either certified under the EU-U.S. or Swiss Privacy Shield Framework and will process all personal data received from EU member states/Switzerland in reliance on the applicable Privacy Shield Framework or that they have been subjected to strict contractual provisions in their contract with us to guarantee an adequate level of data protection for your data.

California Privacy Rights

Pursuant to Section 1798.83 of the California Civil Code, our customers who are California residents have the right to request certain information regarding our disclosure of personal information to third parties for their direct marketing purposes.

You can make a request for this information by emailing us at privacy@jdsupra.com or by writing to us at:

Privacy Officer
JD Supra, LLC
10 Liberty Ship Way, Suite 300
Sausalito, California 94965

Some browsers have incorporated a Do Not Track (DNT) feature. These features, when turned on, send a signal that you prefer that the website you are visiting not collect and use data regarding your online searching and browsing activities. As there is not yet a common understanding on how to interpret the DNT signal, we currently do not respond to DNT signals on our site.

Access/Correct/Update/Delete Personal Information

For non-EU/Swiss residents, if you would like to know what personal information we have about you, you can send an e-mail to privacy@jdsupra.com. We will be in contact with you (by mail or otherwise) to verify your identity and provide you the information you request. We will respond within 30 days to your request for access to your personal information. In some cases, we may not be able to remove your personal information, in which case we will let you know if we are unable to do so and why. If you would like to correct or update your personal information, you can manage your profile and subscriptions through our Privacy Center under the "My Account" dashboard. If you would like to delete your account or remove your information from our Website and Services, send an e-mail to privacy@jdsupra.com.

Changes in Our Privacy Policy

We reserve the right to change this Privacy Policy at any time. Please refer to the date at the top of this page to determine when this Policy was last revised. Any changes to our Privacy Policy will become effective upon posting of the revised policy on the Website. By continuing to use our Website and Services following such changes, you will be deemed to have agreed to such changes.

Contacting JD Supra

If you have any questions about this Privacy Policy, the practices of this site, your dealings with our Website or Services, or if you would like to change any of the information you have provided to us, please contact us at: privacy@jdsupra.com.

JD Supra Cookie Guide

As with many websites, JD Supra's website (located at www.jdsupra.com) (our "Website") and our services (such as our email article digests)(our "Services") use a standard technology called a "cookie" and other similar technologies (such as, pixels and web beacons), which are small data files that are transferred to your computer when you use our Website and Services. These technologies automatically identify your browser whenever you interact with our Website and Services.

How We Use Cookies and Other Tracking Technologies

We use cookies and other tracking technologies to:

  1. Improve the user experience on our Website and Services;
  2. Store the authorization token that users receive when they login to the private areas of our Website. This token is specific to a user's login session and requires a valid username and password to obtain. It is required to access the user's profile information, subscriptions, and analytics;
  3. Track anonymous site usage; and
  4. Permit connectivity with social media networks to permit content sharing.

There are different types of cookies and other technologies used our Website, notably:

  • "Session cookies" - These cookies only last as long as your online session, and disappear from your computer or device when you close your browser (like Internet Explorer, Google Chrome or Safari).
  • "Persistent cookies" - These cookies stay on your computer or device after your browser has been closed and last for a time specified in the cookie. We use persistent cookies when we need to know who you are for more than one browsing session. For example, we use them to remember your preferences for the next time you visit.
  • "Web Beacons/Pixels" - Some of our web pages and emails may also contain small electronic images known as web beacons, clear GIFs or single-pixel GIFs. These images are placed on a web page or email and typically work in conjunction with cookies to collect data. We use these images to identify our users and user behavior, such as counting the number of users who have visited a web page or acted upon one of our email digests.

JD Supra Cookies. We place our own cookies on your computer to track certain information about you while you are using our Website and Services. For example, we place a session cookie on your computer each time you visit our Website. We use these cookies to allow you to log-in to your subscriber account. In addition, through these cookies we are able to collect information about how you use the Website, including what browser you may be using, your IP address, and the URL address you came from upon visiting our Website and the URL you next visit (even if those URLs are not on our Website). We also utilize email web beacons to monitor whether our emails are being delivered and read. We also use these tools to help deliver reader analytics to our authors to give them insight into their readership and help them to improve their content, so that it is most useful for our users.

Analytics/Performance Cookies. JD Supra also uses the following analytic tools to help us analyze the performance of our Website and Services as well as how visitors use our Website and Services:

  • HubSpot - For more information about HubSpot cookies, please visit legal.hubspot.com/privacy-policy.
  • New Relic - For more information on New Relic cookies, please visit www.newrelic.com/privacy.
  • Google Analytics - For more information on Google Analytics cookies, visit www.google.com/policies. To opt-out of being tracked by Google Analytics across all websites visit http://tools.google.com/dlpage/gaoptout. This will allow you to download and install a Google Analytics cookie-free web browser.

Facebook, Twitter and other Social Network Cookies. Our content pages allow you to share content appearing on our Website and Services to your social media accounts through the "Like," "Tweet," or similar buttons displayed on such pages. To accomplish this Service, we embed code that such third party social networks provide and that we do not control. These buttons know that you are logged in to your social network account and therefore such social networks could also know that you are viewing the JD Supra Website.

Controlling and Deleting Cookies

If you would like to change how a browser uses cookies, including blocking or deleting cookies from the JD Supra Website and Services you can do so by changing the settings in your web browser. To control cookies, most browsers allow you to either accept or reject all cookies, only accept certain types of cookies, or prompt you every time a site wishes to save a cookie. It's also easy to delete cookies that are already saved on your device by a browser.

The processes for controlling and deleting cookies vary depending on which browser you use. To find out how to do so with a particular browser, you can use your browser's "Help" function or alternatively, you can visit http://www.aboutcookies.org which explains, step-by-step, how to control and delete cookies in most browsers.

Updates to This Policy

We may update this cookie policy and our Privacy Policy from time-to-time, particularly as technology changes. You can always check this page for the latest version. We may also notify you of changes to our privacy policy by email.

Contacting JD Supra

If you have any questions about how we use cookies and other tracking technologies, please contact us at: privacy@jdsupra.com.

- hide

This website uses cookies to improve user experience, track anonymous site usage, store authorization tokens and permit sharing on social media networks. By continuing to browse this website you accept the use of cookies. Click here to read more about how we use cookies.